UBS Group’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.9M | Buy |
65,188
+21,100
| +48% | +$7.52M | ﹤0.01% | 2436 |
|
|
2025
Q4 | $14.4M | Buy |
44,088
+1,288
| +3% | +$409K | ﹤0.01% | 2917 |
|
|
2025
Q3 | $12.1M | Buy |
42,800
+28,200
| +193% | +$8.18M | ﹤0.01% | 3093 |
|
|
2025
Q2 | $4.08M | Sell |
14,600
-3,000
| -17% | -$850K | ﹤0.01% | 4082 |
|
|
2025
Q1 | $5.48M | Sell |
17,600
-52,000
| -75% | -$15.4M | ﹤0.01% | 3695 |
|
|
2024
Q4 | $18.1M | Sell |
69,600
-80,100
| -54% | -$23.8M | ﹤0.01% | 2436 |
|
|
2024
Q3 | $48.2M | Buy |
149,700
+34,196
| +30% | +$11.2M | 0.01% | 1170 |
|
|
2024
Q2 | $36.1M | Buy |
115,504
+38,504
| +50% | +$11.3M | 0.01% | 1253 |
|
|
2024
Q1 | $21.9M | Sell |
77,000
-228,435
| -75% | -$66.8M | 0.01% | 1616 |
|
|
2023
Q4 | $88M | Buy |
305,435
+157,935
| +107% | +$43M | 0.03% | 636 |
|
|
2023
Q3 | $39.6M | Sell |
147,500
-9,200
| -6% | -$2.3M | 0.01% | 997 |
|
|
2023
Q2 | $34.8M | Buy |
156,700
+20,800
| +15% | +$4.83M | 0.01% | 1034 |
|
|
2023
Q1 | $32.9M | Sell |
135,900
-28,700
| -17% | -$7.05M | 0.01% | 1021 |
|
|
2022
Q4 | $43.2M | Buy |
164,600
+53,300
| +48% | +$14.3M | 0.02% | 894 |
|
|
2022
Q3 | $25.1M | Buy |
111,300
+16,300
| +17% | +$3.95M | 0.01% | 1119 |
|
|
2022
Q2 | $23.1M | Buy |
95,000
+15,000
| +19% | +$3.68M | 0.01% | 1219 |
|
|
2022
Q1 | $19.3M | Buy |
80,000
+64,000
| +400% | +$14.7M | 0.01% | 1443 |
|
|
2021
Q4 | $3.6M | Sell |
16,000
-26,321
| -62% | -$5.56M | ﹤0.01% | 3188 |
|
|
2021
Q3 | $9M | Sell |
42,321
-10,979
| -21% | -$2.53M | ﹤0.01% | 2109 |
|
|
2021
Q2 | $13M | Sell |
53,300
-7,200
| -12% | -$1.77M | ﹤0.01% | 1822 |
|
|
2021
Q1 | $15.1M | Buy |
60,500
+7,500
| +14% | +$1.79M | 0.01% | 1628 |
|
|
2020
Q4 | $12.2M | Buy |
53,000
+7,900
| +18% | +$1.82M | ﹤0.01% | 1702 |
|
|
2020
Q3 | $11.5M | Buy |
45,100
+28,700
| +175% | +$7.11M | ﹤0.01% | 1552 |
|
|
2020
Q2 | $3.87M | Sell |
16,400
-32,400
| -66% | -$7.39M | ﹤0.01% | 2245 |
|
|
2020
Q1 | $9.89M | Sell |
48,800
-32,600
| -40% | -$7.12M | ﹤0.01% | 1421 |
|
|
2019
Q4 | $19.6M | Buy |
+81,400
| New | +$17.9M | 0.01% | 1390 |
|
|
2019
Q3 | – | Sell |
-6,500
| Closed | -$1.2M | – | 7967 |
|
|
2019
Q2 | $1.2M | Sell |
6,500
-600
| -8% | -$107K | ﹤0.01% | 3602 |
|
|
2019
Q1 | $1.35M | Sell |
7,100
-1,600
| -18% | -$306K | ﹤0.01% | 3333 |
|
|
2018
Q4 | $1.69M | Sell |
8,700
-24,300
| -74% | -$4.74M | ﹤0.01% | 3197 |
|
|
2018
Q3 | $6.84M | Sell |
33,000
-500
| -1% | -$98.5K | ﹤0.01% | 2083 |
|
|
2018
Q2 | $6.18M | Buy |
33,500
+25,900
| +341% | +$4.58M | ﹤0.01% | 2160 |
|
|
2018
Q1 | $1.3M | Sell |
7,600
-23,400
| -75% | -$4.3M | ﹤0.01% | 3508 |
|
|
2017
Q4 | $5.39M | Buy |
31,000
+15,100
| +95% | +$2.67M | ﹤0.01% | 2279 |
|
|
2017
Q3 | $2.96M | Buy |
15,900
+1,100
| +7% | +$195K | ﹤0.01% | 2732 |
|
|
2017
Q2 | $2.55M | Sell |
14,800
-10,200
| -41% | -$1.66M | ﹤0.01% | 2786 |
|
|
2017
Q1 | $4.1M | Sell |
25,000
-134,200
| -84% | -$22.3M | ﹤0.01% | 2258 |
|
|
2016
Q4 | $23.3M | Buy |
159,200
+155,500
| +4,203% | +$23.4M | 0.01% | 932 |
|
|
2016
Q3 | $617K | Sell |
3,700
-95,600
| -96% | -$16.2M | ﹤0.01% | 3766 |
|
|
2016
Q2 | $15.1M | Buy |
99,300
+89,002
| +864% | +$13.8M | 0.01% | 1108 |
|
|
2016
Q1 | $1.54M | Sell |
10,298
-6,502
| -39% | -$966K | ﹤0.01% | 2897 |
|
|
2015
Q4 | $2.73M | Sell |
16,800
-171,700
| -91% | -$27M | ﹤0.01% | 2517 |
|
|
2015
Q3 | $26.1M | Sell |
188,500
-18,070
| -9% | -$2.85M | 0.02% | 747 |
|
|
2015
Q2 | $31.7M | Buy |
206,570
+101,670
| +97% | +$16.3M | 0.02% | 720 |
|
|
2015
Q1 | $16.8M | Buy |
104,900
+33,500
| +47% | +$5.28M | 0.01% | 1078 |
|
|
2014
Q4 | $11.4M | Buy |
+71,400
| New | +$11.1M | 0.01% | 1405 |
|
Other funds holding AMGN
VCM
VPM
UBS Group's AMGN Position: Q1 2026 in Review
UBS Group reduced its Amgen (AMGN) stake by 23% in Q1 2026, selling an estimated $341M and leaving 3,148,040 shares worth $1.11B. The position accounts for 0.17% of the portfolio, ranked #116.
UBS Group first reported a position in AMGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.4B in Q1 2025. 3,128 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- UBS Group held 3,148,040 shares of Amgen worth $1.11B as of Q1 2026.
- UBS Group sold 956,484 Amgen shares in Q1 2026, an estimated $341M.
- Amgen made up 0.17% of UBS Group's portfolio in Q1 2026, its #116 holding.
- UBS Group first reported a position in Amgen in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Amgen position peaked at $1.4B in Q1 2025.
- 3,128 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.